AZT logo

ArcticZymes Technologies ASA Stock Price

OB:AZT Community·NOK 1.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

AZT Share Price Performance

NOK 0
-16.30 (-100.00%)
NOK 32.00
Fair Value
NOK 0
-16.30 (-100.00%)
Price NOK 0

AZT Community Narratives

·
Fair Value NOK 32 36.6% undervalued intrinsic discount

Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
NOK 32
36.6% undervalued intrinsic discount
Revenue
17.19% p.a.
Profit Margin
26.96%
Future PE
38.62x
Price in 2029
NOK 38.79

Trending Discussion

Updated Narratives

AZT logo

AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside

Fair Value: NOK 32 36.6% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
3 Rewards

ArcticZymes Technologies ASA Key Details

NOK 128.4m

Revenue

NOK 6.1m

Cost of Revenue

NOK 122.2m

Gross Profit

NOK 108.8m

Other Expenses

NOK 13.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 14, 2026
0.26
95.22%
10.46%
0%
View Full Analysis

About AZT

Founded
1990
Employees
51
CEO
Michael Akoh
WebsiteView website
www.arcticzymes.com

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Recent AZT News & Updates

Recent updates

No updates